3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Endometrial Neoplasms
5
Ovarian Neoplasms
4
Sarcoma
2
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Sarcoma, Endometrial Stromal
1
Recurrence
1
Primary Myelofibrosis
1
Neurofibrosarcoma
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Neoplasms
1
Leiomyosarcoma
1
Genital Diseases
1
Fallopian Tube Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Fulvestrant
3
cobimetinib
2
anlotinib
2
Bevacizumab
2
trametinib
1
selinexor
1
ribociclib
1
relacorilant
1
palbociclib
1
osimertinib
1
olaparib
1
niraparib
1
nintedanib
1
exemestane
1
enzalutamide
1
dabrafenib
1
atezolizumab
1
alectinib
1
abemaciclib
1
Watchful Waiting
1
Vemurafenib
1
Transurethral Resection of Prostate
1
Trabectedin
1
Tamoxifen
1
STX-478
1
Pregnancy Tests
1
Pemetrexed
1
Metformin
1
Letrozole
1
Imlunestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
selinexor
×
Gynecologic
×
Clear all
NCT03555422
2026-04-13
ENGOT-EN5
Karyopharm Therapeutics Inc
Phase 3
Completed
263 enrolled